| Name | Title | Contact Details |
|---|
Rakuten Aspyrian, Inc is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany.
AJAX Health accelerates medical innovation through capital and capabilities. Created in partnership with private equity leaders KKR and Aisling Capital, AJAX invests and takes an operating role in innovative medical companies that improve lives and bring speed, simplicity and cost efficiency to health care.
Chiral Quest is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.
Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver alterations,” in contrast to those merely along for the ride as “passenger alterations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allow us to construct drugs with best-in-class properties from the ground up.